Novo Nordisk Gross Margin 2010-2024 | NVO

Current and historical gross margin for Novo Nordisk (NVO) over the last 10 years. The current gross profit margin for Novo Nordisk as of March 31, 2024 is %.
Novo Nordisk Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $35.55B $30.09B 84.65%
2023-12-31 $33.72B $28.53B 84.60%
2023-09-30 $30.85B $25.96B 84.16%
2023-06-30 $28.44B $24.00B 84.37%
2023-03-31 $26.41B $22.24B 84.23%
2022-12-31 $25.06B $21.03B 83.92%
2022-09-30 $24.32B $20.47B 84.18%
2022-06-30 $23.81B $19.97B 83.89%
2022-03-31 $23.26B $19.40B 83.38%
2021-12-31 $22.40B $18.64B 83.20%
2021-09-30 $21.64B $17.94B 82.91%
2021-06-30 $20.85B $17.30B 82.98%
2021-03-31 $19.93B $16.57B 83.17%
2020-12-31 $19.45B $16.24B 83.51%
2020-09-30 $19.09B $15.98B 83.69%
2020-06-30 $18.74B $15.68B 83.67%
2020-03-31 $18.84B $15.75B 83.62%
2019-12-31 $18.29B $15.28B 83.54%
2019-09-30 $17.43B $14.61B 83.81%
2019-06-30 $17.25B $14.49B 84.03%
2019-03-31 $17.11B $14.39B 84.10%
2018-12-31 $17.10B $14.41B 84.24%
2018-09-30 $17.61B $14.79B 83.98%
2018-06-30 $17.49B $14.68B 83.95%
2018-03-31 $17.33B $14.57B 84.06%
2017-12-31 $16.97B $14.29B 84.20%
2017-09-30 $16.81B $14.15B 84.21%
2017-06-30 $16.73B $14.16B 84.60%
2017-03-31 $16.67B $14.13B 84.78%
2016-12-31 $16.61B $14.06B 84.62%
2016-09-30 $16.56B $14.05B 84.81%
2016-06-30 $16.43B $13.93B 84.83%
2016-03-31 $16.26B $13.82B 84.94%
2015-12-31 $16.06B $13.65B 85.00%
2015-09-30 $15.99B $13.58B 84.94%
2015-06-30 $15.95B $13.51B 84.68%
2015-03-31 $15.92B $13.37B 84.00%
2014-12-31 $15.83B $13.24B 83.60%
2014-09-30 $15.63B $13.09B 83.73%
2014-06-30 $15.31B $12.75B 83.29%
2014-03-31 $15.08B $12.57B 83.31%
2013-12-31 $14.89B $12.37B 83.08%
2013-09-30 $14.58B $12.14B 83.22%
2013-06-30 $14.27B $11.87B 83.14%
2013-03-31 $13.89B $11.53B 82.97%
2012-12-31 $13.48B $11.16B 82.74%
2012-09-30 $13.04B $10.70B 82.03%
2012-06-30 $12.80B $10.42B 81.44%
2012-03-31 $12.52B $10.14B 80.99%
2011-12-31 $12.27B $9.92B 80.82%
2011-09-30 $12.04B $9.68B 80.44%
2011-06-30 $11.85B $9.61B 81.06%
2011-03-31 $11.48B $9.33B 81.24%
2010-12-31 $11.06B $8.97B 81.17%
2010-09-30 $10.66B $8.63B 80.89%
2010-06-30 $10.24B $8.20B 80.02%
2010-03-31 $9.90B $7.88B 79.64%
2009-12-31 $9.67B $7.72B 79.80%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $631.845B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11